drugset / Trial / NCT04887012
Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
NaSingle-groupOpen-labelTreatment
Summary
To study the safety and effectiveness of HLA haploidentical CAR-NK cells targeting CD19 in patients with B-cell non-Hodgkin's lymphoma
Timeline
- Start
- 2021-05-01
- Primary completion
- 2022-05-01
- Completion
- 2024-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 CAR-NK | Cell therapy | — | Intravenous |